Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia

Cancer Letters

Volumn 210, Issue 2, 2004, Pages 171-177

  Lindemalm, Synnöve ^a   Liliemark, Jan ^a   Juliusson, Gunnar ^b   Larsson, Rolf ^c   Albertioni, Freidoun ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chloroadenine; Cladribine; Leukemia; Metabolism; Pharmacokinetics

Indexed keywords

2 CHLOROADENINE; ANTINEOPLASTIC AGENT; CLADRIBINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; HAIRY CELL LEUKEMIA; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADENINE; ADMINISTRATION, ORAL; AREA UNDER CURVE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; TUMOR CELLS, CULTURED;

EID: 2942534191     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.007     Document Type: Article

References (32)

1. Carson D., Wasson D., Kaye J., Ullman B., Martin D., Robins R., Montgomery J. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. USA. 11:1980;6865-6869
2. Seto S., Carrera J., Kubota M., Wasson B., Carson D. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75:1985;377-383
3. Piro L.D., Carrera C.J., Carson D.A., Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322:1990;1117-1121
4. Tallman M.S., Hakimian D., Variakojis D., Koslow D., Sisney G.A., Rademaker A.W., et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 80:1992;2203-2209
5. Karlsson K., Stromberg M., Liliemark J., Delannoy A., Johnson S.A., Porwit A., et al. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients, Br. J. Haematol. 116:2002;538-548
6. Saven A., Carrera C.J., Carson D., Beutler E.J., Piro L. Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma. 5:1991;133-138
7. Delannoy A. 2-Chloro-2′-deoxyadenosine: clinical applications in hematology. Blood Rev. 10:1996;148-166
8. Beutler E., Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA. 93:1996;1716-1720
9. Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J., Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 344:1994;9-13
10. Albertioni F., Pettersson B., Reichelova V., Juliusson G., Liliemark J. Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. Ther. Drug Monit. 16:1994;413-418
11. Lindemalm S., Albertioni F., Liliemark J. Stability and analysis of 2-chloro-2′-deoxyadenosine, 2-chloro-2′-arabino-fluoro-2′- deoxyadenosine and 2-chloroadenine in human blood plasma. Anticancer Drugs. 8:1997;445-453
12. Carson D., Wasson B., Esparza L., Carrera C., Kipps T., Cottam H. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino- fluoro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA. 89:1992;2970-2974
13. Fabianowska-Majewska K., Wyczechowska D. 2-Chloro-2′-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy. Acta Pol. Pharm. 53:1996;231-239
14. Bontemps F., Delacauw A., Cardoen S., Van Den Neste E., Van Den Berghe G. Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2′-deoxyadenosine, Biochem. Pharmacology. 2000;1237-1243
15. Arner E.S., Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 67:1995;155-186
16. Sjoberg A.H., Wang L., Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol. Pharmacol. 53:1998;270-273
17. Avery T., Rehg J., Lumm W., Harwood F., Santana V., Blakley R. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res. 49:1989;4972-4978
18. Robertson L.E., Chubb S., Meyn R.E., Story M., Ford R., Hittelman W.N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 81:1993;143-150
19. Saven A., Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N. Engl. J. Med. 330:1994;691-697
20. Leoni L.M., Chao Q., Cottam H.B., Genini D., Rosenbach M., Carrera C.J., et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc. Natl. Acad. Sci. USA. 95:1998;9567-9571
21. Genini D., Adachi S., Chao Q., Rose D.W., Carrera C.J., Cottam H.B., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 96:2000;3537-3543
22. Chandra J., Mansson E., Gogvadze V., Kaufmann S.H., Albertioni F., Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood. 99:2002;655-663
23. Nomura Y., Inanami O., Takahashi K., Matsuda A., Kuwabara M. 2-Chloro-2′-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia. 14:2000;299-306
24. Ceruti S., Beltrami E., Matarrese P., Mazzola A., Cattabeni F., Malorni W., Abbracchio M.P. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. Mol. Pharmacol. 63:2003;1437-1447
25. Liliemark J., Juliusson G. Cellular pharmacokinetics of 2-Chloro-2'-Deoxyadenosine Nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin. Cancer Res. 1:1995;385-390
26. Christensen L.F., Broom A. Synthesis and biological activity of selected 2, 6-disubstituted-(2-deoxy-a-and-b-D-erythro-pentofuranosyl)purines. J. Med. Chem. 15:1972;735-739
27. Brown G., Weliky V. 2-Chloroadenine and 2-chloroadenosine. J. Org. Chem. 23:1958;125-126
28. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA), Int. J. Cancer. 50:1992;177-185
29. Albertioni F., Juliusson G., Liliemark J. On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. Eur. J. Clin. Pharmacol. 44:1993;579-582
30. Liliemark J., Albertioni F., Hassan M., Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 10:1992;1514-1518
31. Saven A., Cheung W.K., Smith I., Moyer M., Johannsen T., Rose E., et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J. Clin. Oncol. 14:1996;978-983
32. Van Den Neste E., Bontemps F., Delacauw A., Cardoen S., Louviaux I., Scheiff J.M., et al. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′- deoxyadenosine. Leukemia. 13:1999;918-925